Phagocytosis – eliminating millions of dead cells every day – requires specialized cells such as macrophages, the true professionals, which migrate to engulf waste and dying cells. But they are not the only ones that can perform this task, as scientists at Howard Hughes Medical Institute (HHMI) discovered when they investigated hair follicle stem cells (HFSCs), a tissue in constant regeneration, to clarify how dying cells are detected and cleared in the epithelium and the mesenchyme.
Zymedi Co. Ltd. has patented compounds acting as lysyl tRNA synthetase (KARS) inhibitors and reported to be useful for the treatment of cancer metastasis, inflammation, fibrosis and cardiovascular disorders.
Lucy Therapeutics Inc. has disclosed new mitochondrial F1F0 ATPase hydrolase inhibitors potentially useful for the treatment of cancer, acute coronary syndrome, ischemia, neurodegeneration and Parkinson's disease.
Several recent Janssen Pharmaceutica NV patents describe new NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, dementia, Huntington’s, Parkinson’s, Alzheimer’s and motor neuron diseases.
Purdue Research Foundation has discovered compounds for inhibiting protein aggregation potentially useful for the treatment of wild-type transthyretin amyloidosis, type 2 diabetes, amyotrophic lateral sclerosis and more.
Recent studies have shown that up-regulation of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) was able to induce fetal hemoglobin synthesis in human primary erythroblasts.
Invenra Inc.’s bispecific antibody, INV-724, developed for the treatment of neuroblastoma, has been awarded orphan drug and rare pediatric disease designations by the FDA.
Researchers from Tanta University and affiliated organizations reported the discovery and preclinical characterization of novel pazopanib analogues as potential anticancer agents.
RSS
